文献速递精神分裂症与精神病性障碍儿童青少年精神

青少年精神科患者使用多西环素与精神分裂症风险:一项模拟目标试验

Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial.
PubMed 文献 · Am J Psychiatry · 2025-11-05

该研究利用芬兰全国健康登记数据,模拟目标试验,纳入1987至1997年出生、13至18岁曾就诊青少年精神科且使用过抗生素的个体,随访至30岁。结果显示,与使用非多西环素抗生素者10年精神分裂症风险2.1%相比,多西环素低、高累积剂量组风险显著降低(风险比0.70),中剂量组风险比0.65但置信区间跨1。结论提示多西环素可能降低青少年精神科患者精神分裂症风险,但属初步发现。

要点

  • 青少年精神科使用抗生素者中,多西环素暴露与10年精神分裂症风险降低相关。
  • 低剂量和高剂量多西环素风险比均为0.70,中剂量风险比0.65但无统计学显著性。
  • 研究为观察性模拟目标试验,不能确立因果关系,需谨慎解读。

核心结论

  • 在青少年精神科患者中,多西环素暴露与10年精神分裂症风险降低相关,提示其可能具有预防潜力,但证据为初步性。

研究设计与样本

  • 采用模拟目标试验设计,基于芬兰全国健康登记数据,纳入1987至1997年出生、13至18岁曾就诊青少年精神科且使用过任何抗生素的个体,随访至30岁。

主要发现

  • 共纳入56,395名青少年精神科患者且使用过抗生素,其中16,189名(28.7%)使用过多西环素。
  • 随访10年时,使用非多西环素抗生素者的精神分裂症风险为2.1%(95% CI=1.9, 2.3)。
  • 多西环素低累积剂量(<1,499 mg)组10年风险为1.4%,风险比=0.70(95% CI=0.48, 0.85)。
  • 多西环素中累积剂量(1,500-2,999 mg)组10年风险为1.4%,风险比=0.65(95% CI=0.25, 1.04)。
  • 多西环素高累积剂量(≥3,000 mg)组10年风险为1.5%,风险比=0.70(95% CI=0.43, 0.97)。

关键数值与推荐

  • 多西环素累积剂量分组标准:无使用、低使用(<1,499 mg)、中使用(1,500-2,999 mg)、高使用(≥3,000 mg)。
  • 主要结局为记录的精神分裂症诊断,随访从首次配发抗生素处方至30岁。

临床怎么用

  • 目前不应基于此观察性研究改变青少年精神科抗生素使用或精神分裂症预防策略。
  • 多西环素潜在神经保护作用需在随机对照试验中进一步验证,临床决策应个体化。

局限性

  • 研究为观察性模拟目标试验,存在未测量混杂可能,不能证明因果关系。
  • 中剂量组风险比置信区间包含1,统计学显著性不足。
  • 结果基于芬兰登记数据,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: As many as half of individuals who develop psychosis had attended child and adolescent psychiatric services at some stage in childhood, highlighting substantial opportunities for prevention within these services if an effective preventive intervention were identified. The authors hypothesized that adolescent psychiatric patients exposed to doxycycline, an antibiotic with putative neuroprotective properties, would have a lower risk of developing schizophrenia. METHODS: This was an emulated target trial using nationwide Finnish health register data on all individuals born between 1987 and 1997 who attended adolescent psychiatric services between ages 13 and 18 and had used any antibiotics. Individuals were followed from first dispensed antibiotic prescription up to age 30. The main outcome was recorded schizophrenia diagnosis. The g-formula was used to estimate schizophrenia risk across doxycycline exposure levels (cumulative dose doxycycline use: no doxycycline use; low use, <1,499 mg; medium use, 1,500-2,999 mg; high use, ≥3,000 mg) during different follow-up periods. RESULTS: A total of 56,395 individuals had attended adolescent psychiatric services and had used antibiotics; of these, 16,189 (28.7%) had used doxycycline. The risk of schizophrenia after 10 years of follow-up was 2.1% (95% CI=1.9, 2.3) for individuals who had used non-doxycycline antibiotics. In comparison, the risk of schizophrenia at 10 years was significantly lower in adolescent psychiatric patients treated with doxycycline (low cumulative dose: 1.4%, risk ratio=0.70, 95% CI=0.48, 0.85; medium cumulative dose: 1.4%, risk ratio=0.65, 95% CI=0.25, 1.04; high cumulative dose: 1.5%, risk ratio=0.70, 95% CI=0.43, 0.97). CONCLUSIONS: These findings raise the tentative but exciting possibility that doxycycline treatment may reduce schizophrenia risk in adolescent psychiatric patients.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lång U, Metsälä J, Ramsay H, et al. Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial. Am J Psychiatry. 2025. PMID: 41190738. doi:10.1176/appi.ajp.20240958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。